New results from the use of bisphosphonates in cancer patients

Current Opinion in Supportive and Palliative Care

Volumn 3, Issue 3, 2009, Pages 213-218

  Coleman, Robert ^a   Gnant, Michael ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adjuvant therapy; Bisphosphonates; Bone metastases; Cancer treatment induced bone loss; Skeletal related events

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE MARROW CELL; BONE TUMOR; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; HUMAN; MALE; METASTASIS; OSTEOLYSIS; PATHOLOGY; PATHOPHYSIOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 72049088878     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0b013e32832f4149     Document Type: Article

References (55)

1. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12 (20 Suppl):6243-6249.
2. Clines GA, Guise TA. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Endocr Relat Cancer 2005; 12:549-583.
3. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584-593.
4. Winter MC, Holen I, Coleman RE. Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34:453-475.
5. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, et al. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113:364- 371.
6. Ottewell PD, Monkkonen H, Jones M, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008; 100:1167-1178. Preclinical in-vivo study indicating remarkable sequence-dependent synergy between chemotherapy and zoledronic acid.
7. Winter MC, Thorpe HC, Burkinshaw R, et al. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response: exploratory evidence for direct antitumor activity in breast cancer. Cancer Res 2008; 69 (Suppl 2); abstract 5101.
8. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008; 98:1736-1740.
9. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19:420-432. Consensus document on the use of bisphosphonates in malignancy. Useful practice guideline.
10. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97:59-69.
11. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113:193- 201. Evaluation of biochemical response to bisphosphonate treatment. Demonstrated that normalisation of bone resorption was associated with improved disease outcomes.
12. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006; 20:4895-4900.
13. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009; 27:1564- 1571. Important proof of concept study showing ability to reverse biochemical 'resistance' with a novel osteoclast inhibitor.
14. Lester J, Dodwell D, McCloskey E, Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 2005; 31:115-142.
15. Coleman RE, Body J-J, Gralow JR, Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev 2008; 34 (Suppl 1):S31-S42.
16. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007; 8:119-127.
17. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008; 26:1051-1057. First publication to define the bone effects of 5 years adjuvant treatment with an aromatase inhibitor.
18. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant.
19. Smith MR, Boyce SP, Moyneur E, et al. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol 2006; 175:136-139.
20. Hadji P, Body J-J, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19:1407- 1416. Useful consensus guidelines for defining management strategies for the treatment of bone loss in breast cancer.
21. Reid DM, Doughty J, Eastell R, et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 2008; 34 (Suppl 1):S3-S18. UK consensus guidelines for defining management strategies for the treatment of bone loss in breast cancer.
22. Vehmanen L, Saarto T, Elomaa I, et al. Long-term impact of chemotherapyinduced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001; 37:2373-2378.
23. Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997; 15:955-962.
24. Fuleihan Gel H, Salamoun M, Mourad YA, et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005; 90:3209-3214.
25. Brown JE, Ellis SP, Lester JE, et al. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 2007; 13:5406- 5410.
26. Hershman DL, McMahon DJ, Crew KD, et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for earlystage breast cancer. J Clin Oncol 2008; 26:4739-4745.
27. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25:820-828.
28. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9:840-849. Important study defining the degree of bone loss from endocrine treatments including ovarian suppression for early breast cancer and protective effects of zoledronic acid. Also provides data on partial recovery of BMD on cessation of endocrine treatments.
29. Hines SL, Mincey BA, Sloan JA, et al. N02C1: a phase III randomized, placebo-controlled, double-blind trial of risedronate for prevention of bone loss in premenopausal women undergoing adjuvant chemotherapy for breast cancer. J Clin Oncol 2009; 27:1047-1053. Provides important observation that standard osteoporosis treatment may be insufficient to prevent bone loss caused by chemotherapy induced ovarian suppression.
30. Saarto T, Vehmanen L, Blomqvist C, et al. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 2008; 26:4289-4295.
31. Confavreux CB, Fontana A, Guastalla JP, et al. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007; 41:346-352.
32. Greenspan SL, Brufsky A, Lembersky BC, et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebocontrolled clinical trial. J Clin Oncol 2008; 26:2644-2652. Study reporting on the efficacy of an osteoporosis schedule for the treatment of bone loss in postmenopausal breast cancer patients.
33. Lester JE, Dodwell D, Purohit OP, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008; 14:6336- 6342. First study to report the efficacy of an osteoporosis dose of ibadronate in the treatment of aromatase inhibitor induced bone loss.
34. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25:829-836.
35. Bundred NJ, Campbell ID, Davidson N. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study results). Cancer 2008; 112:1001-1010.
36. Eidtmann H, Bundred N, De Boer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow-up of ZO-FAST. Presented at 31st San Antonio Breast Cancer Symposium; 10-14 December 2008; San Antonio, TX. Abstract 44.
37. Brufsky A, Bosserman L, Caradonna R, et al. Zoledronic acid (ZA) prevents aromatase inhibitor (AI)-associated bone loss in postmenopausal women with early breast cancer: 36-month follow-up of the Z-FAST study [poster]. Presented at 6th European Breast Cancer Conference; 15-19 April 2008; Berlin, Germany. Abstract 494.
38. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001; 345:948-955.
39. Bruder JM, Ma JZ, Wing N, et al. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy. J Clin Densitom 2006; 9:431-437.
40. Greenspan SL, Nelson JB, Trump DL, Resnick NM. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007; 146:416- 424.
41. Israeli RS, Rosenberg SJ, Saltzstein DR, et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007; 5:271-277.
42. Ryan CW, Huo D, Demers LM, et al. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006; 176:972-978.
43. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169:2008- 2012.
44. Casey R, Love W, Mendoza C, et al. Zoledronic acid as adjunct to androgen deprivation therapy reduces bone loss in men with prostate cancer [poster]. Presented at 21st Annual EAU Congress; 5-8 April 2006; Paris, France. Abstract 139.
45. Michaelson MD, Kaufman DS, Lee H, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007; 25:1038-1042.
46. Powles T, Paterson A, McCloskey E, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res 2006; 8:R13.
47. Diel IJ, Jaschke A, Solomayer EF, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol 2008; 12:2007-2011. Update of ground-breaking study of adjuvant bisphosphonates in early breast cancer.
48. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19:10-17.
49. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer 2007; 96:1796-1801.
50. Kristensen B, Ejlertsen B, Mouridsen HT, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol 2008; 47:740-746.
51. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21:1453-1460.
52. Curtis JR, Westfall AO, Cheng H, et al. Benefit of adherence with bisphosphonates depends on age and fracture type: results froman analysis of 101, 038 new bisphosphonate users. J Bone Miner Res 2008; 23:1435-1441.
53. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 2009; 360:679-691. Ground-breaking study indicating adjuvant role for zoledronic acid in endocrinesensitive premenopausal breast cancer.
54. Shiozawa Y, Havens AM, Pienta KJ, et al. The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 2008; 22:941-950.
55. Paget S. Secondary growth in cancer of breast. Lancet 1889; 571-572.